Current therapeutic options for lysosomal storage disorders have been shown to be effective but limited
Lysosomal storage disorders are a group of more than 40 heritable diseases that are caused by the pronounced deficiency of one or more lysosomal enzymes. 1 This loss in enzymatic activity results in the progressive accumulation of undegraded substrate within the lysosomes with resultant engorgement of the organelle. This leads to cellular and tissue damage, subsequent organ dysfunction, and in some diseases to early mortality. Although the incidence of individual LSDs can be quite low, as a group they occur in approximately 1 in 7500 live births, and as such represent one of the more prevalent groups of genetic diseases in humans. Currently, treatments for these rare disorders are limited to bone marrow transplantation and enzyme
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Prospects
Candidate in vivo gene transfer vectors such as AAV8 for potential application in the treatment of LSDs will be selected for further characterization Issues pertaining to safety, readministration of vector and manufacturing will be improved Performance of the vector platforms in more relevant larger animal models will be addressed The feasibility and necessity of incorporating gene regulation elements will be evaluated Candidate lysosomal storage disorders with minimal CNS disease will be targeted for clinical studies Methods to deliver gene or cell therapies that result in the global rescue of CNS disease will be developed replacement therapy. 2 The latter has been shown to be effective in the treatment of the non-neuropathic form of Gaucher disease 3 and of Fabry disease, 4, 5 and enzyme replacement therapy is currently being developed for several other LSDs such as mucopolysaccharidosis I (MPS I), II and VI, Pompe disease, and Niemann-Pick B disease. However, because these enzymes generally have short circulating and intracellular half-lives, therapy requires regular, often biweekly, parenteral administrations of relatively large amounts of the relevant enzyme. Repeated bolus administrations of enzyme increase the likelihood of an immune response against the infused proteins, particularly in patients with null mutations, and this could affect the efficacy of subsequent treatments. Furthermore, because systemically administered enzyme is unable to traverse the blood-brain barrier, enzyme therapy is only effective for those manifestations that do not involve the central nervous system (CNS). Therefore, other approaches, including the use of geneand cell-based therapies that offer the opportunity for a more prolonged therapeutic effect than can be realized with enzyme replacement therapy, as well as the possibility of treating the CNS, are also being evaluated.
Lysosomal storage disorders are good candidates for therapy by gene transfer
There are several features of LSDs that make them particularly attractive candidates for intervention by gene therapy. For one, they are generally well-characterized single gene disorders. Importantly, it has also been shown that a proportion of many newly synthesized lysosomal enzymes are secreted into systemic circulation. Enzymes secreted in this way are recaptured by adjacent and distant cells, primarily through the cationindependent mannose-6-phosphate receptor, which is present, albeit in different amounts, on the surface of virtually all cells. 1 Localized gene transduction of a depot organ such as the liver or muscle could allow for secretion of therapeutic levels of the affected enzymes into circulation. The amount of enzyme required for correction will vary with each disease, but may be only 1-10% of normal levels, based on the observed enzyme levels in individuals with milder, late-onset disease. In this regard, the potency of the gene transfer vectors necessary for facilitating the production of therapeutic levels of these enzymes may not need to be very high. Although it is unclear whether sustained overexpression of the hydrolases will have untoward consequences, tight regulation of enzyme production levels is unlikely to be necessary in part because the pH optimas for their enzymatic activities are likely to render them inactive in circulation at neutral pH. Moreover, a number of genetically engineered mouse models as well as naturally occurring mouse and large animal models of LSDs are available, which should allow assessment of these predictions. 6 Early clinical studies using ex vivo gene therapy vectors were ineffective Early attempts at gene therapy for subjects with the lysosomal storage diseases Gaucher, Hunter and Hurler were with transplanted retrovirally transduced bone Nevertheless, with ongoing improvements in vectors and processes for transduction, this approach continues to be of interest for use in LSDs. [8] [9] [10] [11] Recent improvements include the development and use of cytokine combinations that induce hematopoietic cell cycling to enhance retroviral transduction, 12 pseudotyped virions with envelopes that recognize different and perhaps more abundant receptors in the target cells, 13 lentiviral vectors that infect nondividing cells with greater efficiency, 14 and methods to enrich for the transduced cells prior to transplantation. 10 The adaptation of some of these methods has led to clinical success in treating humans with the genetic disorder severe combined immunodeficiency disease (SCID). 15 However, this outcome was due in part to the strong positive selective pressure provided to the corrected lymphoid progenitors upon gene transfer and this is unlikely to occur in corrected cells from LSDs patients. Moreover, two cases of a T-cell leukemia-like disease was recently noted in the treated SCID patients that may have resulted from vector integration. This observation together with the finding that some myeloablation is likely necessary for efficient engraftment of transduced stem cells makes this gene therapy approach less compelling, particularly for those LSDs where enzyme replacement therapy is available.
Proof of concept for use of in vivo gene therapy of LSDs has been demonstrated with different vector platforms and in several animal models
The concept of directly transducing a depot organ to effect the production and secretion of lysosomal enzymes to treat the visceral disease has been demonstrated using a variety of gene delivery systems (Table 1) . Understandably, the initial focus of interest has been directed primarily at those LSDs with no or minimal neurological involvement, and for which a viable animal model is available.
Since systemic delivery of recombinant adenoviral vectors results in efficient transduction of the liver and high-level expression and secretion of lysosomal enzymes, a large number of studies have been performed with this vector. 16, 17 Intravenous delivery of the corresponding recombinant adenoviral vector provided highlevel secretion from the liver, and importantly, re-uptake of the lysosomal enzymes by other affected tissues. Depending on the dose of virus used, the levels of enzyme attained in the different tissues varied from 10-to 1000-fold higher than normal levels. In all cases, reconstitution of the enzymes to these levels was sufficient to reduce rapidly the abnormal storage in the lysosomes to normal or near normal levels.
However, these studies also showed that expression of the desired protein was transient, declining to basal levels within several weeks. Moreover, an inflammatory response that included a significant cytotoxic T-lymphocyte response was observed that likely attenuated expression. Hence, while these studies demonstrated the potential of in vivo gene therapy for LSDs, they also highlighted the need for significant improvements in the performance of the adenoviral vectors before clinical studies can usefully be contemplated. The so-called 'gutless', 'PAV', or helperdependent vectors which are essentially devoid of viral genes, are purportedly less inflammatory, effect less liver toxicity, and support greater longevity of transgene expression. Although these vectors are presently difficult to produce in large quantities and with high purity, their superior properties support their further evaluation in animal models of LSDs.
Synthetic vectors in the form of cationic lipids or polymers have also been considered for in vivo gene therapy of LSDs. 18 Since synthetic vectors are nonproteinaceous, a significant advantage is their ability to be readministered following the attenuation of gene expression. However, the therapeutic window of current formulations of synthetic vectors is quite narrow and improvements in their transduction activity as well as their toxicity profile are necessary. 19 Another nonviral approach is the use of encapsulated gene-modified cells or organoids. Implantation of nonautologous cells expressing b-glucuronidase has been shown to alleviate some of the storage burden in MPS VII mice. 20 However, expression was transient and was associated with the induction of antibodies against the enzyme. Limitations associated with the number of cells that can be encapsulated in the current devices, coupled with the potential for dissolution of the membrane biomaterials with ensuing loss of cell viability or escape of the cells need to be further addressed before this can be considered for human application.
AAV serotypes with improved liver transduction activity are a promising vector platform for gene therapy of LSDs A viral vector that is gaining increasing interest for use in lysosomal storage and other genetic diseases is the adeno-associated viral vector. 21 AAV reportedly exhibits low toxicity and supports long-term transgene expression in mice as well as large animals. [22] [23] [24] Although the vector has a limited capacity for inserted sequences, this is not problematic for most of the cDNAs that encode lysosomal enzymes, since they are relatively small. Several distinct AAV serotypes have been isolated, of which AAV2 has been the most studied. Recombinant AAV2 vectors have so far been constructed for the LSDs, Fabry, 24, 25 Pompe, 26 MPS VII, 27 MPS I, and MPS IIIB. 28 Systemic delivery of recombinant AAV2 encoding agalactosidase A into Fabry mice, or encoding b-glucuronidase into neonatal MPS VII mice, resulted in the reconstitution of the respective enzymes in several tissues to 10-80% of normal levels. These levels are 100-to 1000-fold lower than those attained using recombinant adenoviral vectors, despite the use of much higher doses of AAV2. The kinetics of expression were consistent with those reported previously for AAV2 vectors containing other transgenes, with peak expression levels generally attained between 2 and 4 weeks, and these levels persisting Gene therapy of lysosomal storage disorders SH Cheng and AE Smith for several months post-treatment. Although there was only a modest increase in enzyme levels in some of the tissues, they were sufficient to reduce measurably the amount of the substrates that had accumulated in the different animal models. This observation supports the notion that continuous expression of low levels of enzyme activity is sufficient to reduce the extent of storage in the lysosomes. However, the kinetics for the reduction of the storage materials were slower in the AAV-than in adenoviral-treated animals, with the AAV2-treated animals requiring several more weeks to effect clearance.
When coupled with its positive safety profile, these results suggest that AAV2 vectors have great potential for treating LSDs. However, since AAV2-mediated expression levels were relatively low and close to the threshold for therapeutic efficacy in some of the affected tissues, an improvement in transduction activity would be beneficial. In this regard, other AAV serotypes such as AAV1, and in particular AAV8, have recently been shown to have substantially greater liver transduction activity than AAV2. 29 The 10-to 100-fold higher expression levels attained with AAV8 were correlated with a higher number of transduced hepatocytes and greater persistence of vector DNA. Moreover, AAV8 was shown to have a low reactivity to neutralizing antibodies directed to human AAVs. This relative lack of preexisting immunity to AAV8 coupled with its superior tropism for liver argues that it is a good candidate for further evaluation as a vector for gene therapy of LSDs. However, the induction of a humoral response to the viral proteins following the first administration will present challenges for subsequent readministrations. Although several strategies to overcome this limitation have been reported, none are facile or involve the use of clinically approved agents.
Feasibility of in vivo gene therapy of LSDs with retroviral vectors has been demonstrated
Yet another vector that is under consideration for in vivo gene therapy of LSDs is the oncoretroviral vector. As these vectors have the capacity to integrate into the host genome, they offer the possibility for long-term expression. Both Moloney murine leukemia virus (MLV)-based and lentiviral-based retroviral vectors have been shown to be capable of transducing hepatocytes with sufficient efficiency to facilitate the production and secretion of lysosomal enzymes. 30, 31 Intravenous delivery to MPS VII mice of either a MLV or lentiviral vector encoding bglucuronidase resulted in expression of enzyme to approximately 1% of normal levels in the liver. Expression was sustained for the duration of the studies (3.5-5 months) and was associated with a reduction in lysosomal storage. As these vectors preferentially transduce replicating hepatocytes, improved transfection was realized when the animals were pretreated with hepatocyte growth factor. Greater transduction of hepatocytes (2-20%) could also be attained when the retroviral vectors were administered to neonatal animals as was the case in the recent study in MPS VII dogs. 32, 33 Clonal expansion of the transduced hepatocytes during liver development resulted in the production of b-glucuronidase levels that were within the normal range. These expression levels were sustained in the dogs for several months and were associated with dramatic improvements in the clinical manifestations. Although this intervention is conceivable for humans, implementation would necessarily require an assessment of the risk for insertional mutagenesis, as well as the detection of disease at a very early stage.
Use of liver-specific promoters minimizes the induction of antibodies to the transgene product Expression of lysosomal hydrolases following viralmediated gene transfer to immunocompetent mouse models of LSDs is invariably associated with the generation of a robust humoral response against the enzymes. This has the effect of extinguishing transgene expression and thereby limiting the duration of therapy. This problem is likely to be particularly pertinent in LSD subjects that harbor null mutations. The proportion of patients among the different LSDs carrying null mutations is varied but can be as high as 70% as in the case of Hurler syndrome. However, it has been shown that this immune response can be circumvented in both adenovirus-and AAV-treated animals, provided a tissuerestricted promoter was used to direct the transgene expression. 34 Systemic injection of either a recombinant adenoviral or AAV vector in which the transgenes were placed under the transcriptional control of liverrestricted promoters reduced the extent of antibodies induced and increased the longevity of transgene expression in immunocompetent mice. The reduced tendency to provoke an immune response is thought to be related to the reduced expression of the transgene in antigen-presenting cells.
In Fabry mice, injection of an AAV vector encoding agalactosidase A under the control of a chimeric human liver-restricted promoter consisting of two copies of the prothrombin enhancer linked to a human serum albumin promoter resulted in undiminished expression for up to 1 year. 35 In contrast to Fabry mice treated with a CMV expression cassette, no antibodies to the transgene product were detected in the animals treated with the liver-restricted promoter cassette. The ability of this chimeric promoter to sustain prolonged expression in larger animals such as in a nonhuman primate has also been demonstrated.
Relative ability of the liver, muscle, and lung to support the secretion of lysosomal enzymes has been evaluated Although early in vivo gene therapy efforts for LSDs have focused primarily on the use of the liver as a depot for the production of lysosomal enzymes, consideration has also been given to skeletal muscle and lung as alternate portals. The liver was selected in part because of the tropism of the adenoviral and AAV vectors for this organ. The rationale for selecting hepatocytes as the target for genetic modification was also supported by the knowledge that they are adept at secreting a variety of proteins. However, parenteral administration of viral Gene therapy of lysosomal storage disorders SH Cheng and AE Smith vectors, particularly adenoviral vectors, has been shown to be associated with liver toxicity. This characteristic is obviously undesirable, especially for those LSDs where liver function is already compromised. Systemic delivery also carries the potential risk of transfecting the gonads and of subsequent germline alteration. Using the skeletal muscle as the depot in lieu of the liver circumvents some of these concerns. Using intramuscular injection to produce lysosomal enzymes has been reported for MPS VII, 36 Pompe disease, 26, 37, 38 and Fabry disease. 25 Although high levels of localized expression of the enzymes could be realized in the muscle, only very low levels of the enzymes were secreted into the circulation. In the case of MPS VII and Pompe disease, these levels were determined to be insufficient to provide therapeutic benefit to affected tissues that were distant from the injected muscle. These findings were consistent with the report by Raben et al showing that the muscle was significantly less efficient than the liver at secreting the lysosomal enzyme aglucosidase for Pompe disease. 39 However, these observations did not extend to Fabry disease. Despite attaining only low-level secretion of a-galactosidase A, correction of the storage defect was observed not only in the injected muscle but also globally in AAV2-treated Fabry mice. Therefore, it would appear that the selection of muscle as a depot organ might be applicable for use in some but not all LSDs. Perhaps the use of other AAV serotypes, such as AAV1 or AAV7 that reportedly exhibit higher transduction efficiencies in muscle than AAV2, could further improve the utility of this organ for the production of lysosomal enzymes. 29 Another organ that is gaining interest as a metabolic factory for the production and secretion of therapeutic proteins into systemic circulation is the lung. Use of the lung as a portal for systemic delivery of proteins offers several advantages. Foremost is the large lumenal surface area of the lung that can be accessed noninvasively by liquid or dry powder aerosols. The lung also has an extensive capillary network that could support the delivery of proteins into the systemic circulation. Presently, a number of metabolic hormones such as insulin and growth hormone are under consideration for systemic delivery by pulmonary inhalation. 40 Restricting delivery to the lumen also limits the dissemination and therefore any systemic toxicity that may be associated with the gene transfer vector. Finally, several vector systems, including adenoviral, AAV5 and pseudotyped lentiviral vectors have been shown to transduce airway epithelial cells after pulmonary delivery. 41, 42 The feasibility of genetically modifying the lung and using this as a portal to administer proteins into the blood has been demonstrated for the lysosomal enzyme a-galactosidase A 43 and also for erythropoietin (epo) and factor IX. 44 Instillation of a recombinant adenoviral vector encoding a-galactosidase A into Fabry mice resulted in high level expression in the lung, secretion into the circulation and subsequent uptake of the lysosomal enzyme by the visceral organs. The levels of enzyme detected in the different organs were sufficient to reduce the burden of storage in the affected lysosomes. Although expression in the lung was transient using a recombinant adenoviral vector, expression kinetics were dramatically improved when an AAV5 vector was used for factor IX and epo. The availability of vectors that support high and sustained expression of proteins in the lung and of methods to deliver these in a noninvasive manner to the lumen suggest that the lung may be a viable alternative depot for the production of lysosomal enzymes. As for the gene delivery vectors, the final selection of the depot organ of choice will likely depend on the particulars of the LSDs. A better understanding of the relative abilities of the different organs to confer the necessary post-translational modifications to facilitate effective targeting of the enzymes to the lysosomal compartment may also aid with the selection process.
Encouraging progress has been made in gene therapy of LSDs with CNS disease
To treat LSDs with CNS manifestations requires the development of strategies that not only bypass the physical and blood-brain barriers but that also support the delivery of enzyme throughout the brain. A further challenge for gene transfer within the CNS is the relatively quiescent state of the resident cells that precludes the use of vectors requiring cell division for transduction. Nevertheless, there have been ample demonstrations of the feasibility of gene therapy with several vector platforms in animal models of LSDs with CNS involvement. Intraventricular or stereotactic injections of recombinant adenoviral, AAV, lentiviral, and herpes simplex viral (HSV) vectors into various cerebral structures can result in transduction of both neuronal and glial cells. Of these, AAV and lentiviral vectors appear to be gaining increasing favor because of their safety profile, and their ability to transduce apparently quiescent cells within the CNS and to confer prolonged expression.
Intracranial injections of recombinant AAV2 45 or feline immunodeficiency viral 46 vectors encoding b-glucuronidase into MPS VII mice resulted not only in the correction of the characteristic cellular pathologies but also in improvements in cognitive function. A similar demonstration of protection from disease-associated pathology was also reported for metachromatic leukodystrophy using a lentiviral vector encoding the lysosomal enzyme arylsulfatase A. 47 In all cases, although expression of the enzymes was concentrated at the sites of injection, pathology resulting from storage was reduced in most areas of the brain. This suggested that the enzyme was secreted from the transduced cells and taken up by uninfected adjacent cells, resulting in a zone of correction that extended beyond the site of injection. In addition to enzyme diffusion, evidence has also been presented suggesting that the lysosomal enzymes could be further distributed by axonal transport and by cells of the rostral migratory stream. 48 Further improvement in the biodistribution of the enzyme in MPS VII-injected mice could also be realized through the incorporation of protein transduction motifs such as that derived from HIV Tat. 49 While these results in LSDs mouse models are encouraging, confirmatory studies are required to ascertain whether these observations are translatable to animals with larger brains. In addition, although a few of the studies were performed in adult mice with developed CNS pathology rather than very young animals, it will be important to determine the temporal window for effective interventional therapy.
Gene therapy of lysosomal storage disorders SH Cheng and AE Smith Summary Significant progress has been made in studies of gene therapy for lysosomal storage disorders. While the ability to deliver therapy to the CNS is still at a formative stage, the ability to treat the visceral component of the disease, particularly using the recently described gene transfer vectors, appears feasible. Those LSDs that lack or have only moderate CNS disease could therefore be initially considered for therapy using this approach. Examples of such LSDs include Type I Gaucher disease, Fabry disease, Niemann-Pick B disease, Pompe disease, MPS IS, IH/S, IV and VI.
Prospects
Although more validation is required, the reported higher liver transduction activity of AAV8, coupled with its good safety profile and ability to confer long-term expression suggest that this is the vector choice for evaluation in human clinical studies. Studies to confirm that AAV8 transduces human hepatocytes with high efficiency, as seen in mouse models, and that pre-existing neutralizing antibodies to AAV8 are present at a low frequency in the general population are undoubtedly ongoing. However, depending on the dose of vector needed in humans, consistent manufacture of clinical grade AAV vectors at scale may still present a technical challenge. Other issues include the possibility of neutralizing antibodies generated against the newly synthesized enzymes and the ability to readminister the recombinant virus. While the former could be addressed in part through the use of tissue-restricted promoters, the possible incorporation of gene regulation or gene switch technologies may further alleviate this safety concern. 50 However, readministration of the recombinant virus without the unwieldy use of additional manipulations remains a significant challenge. Most animal studies would predict that AAV-mediated gene expression is likely to persist for a very significant period in time. It is quite possible that the antibody titer to the virus will drop sufficiently during the intervening period to allow readministration.
There is clearly much optimism for the potential use of gene therapy for LSDs, at least initially, for those with minimal CNS involvement. Over the past few years, investigators have better defined what constitutes an effective and safe gene transfer vector for use in this group of metabolic disorders. If the remaining issues associated with the viral gene delivery vectors can be adequately addressed over the next period, it is likely renewed clinical studies for LSDs will proceed.
